CVS/pharmacy looks to attract Tricare members with new online service
WOONSOCKET, R.I. — CVS/pharmacy has launched a new service on its CVS.com website to assist military service members, veterans and their families who need to transfer their prescriptions to a pharmacy that lets them continue using their Tricare prescription insurance coverage.
Tricare members will find at CVS.com/tricare all of the information they need to transfer their prescriptions to one of CVS/pharmacy’s 7,300 pharmacies across the United States. To help raise awareness of CVS/pharmacy’s new Web page for Tricare members, the company will donate $3 to the USO for every person who visits the site between Jan. 1 and Jan. 31, up to a total of $50,000.
"CVS/pharmacy is committed to helping Tricare members on their path to better health, which is why we want to make it as easy as possible for members whose insurance may no longer be accepted at their current pharmacy to transfer their prescriptions to us," stated Papatya Tankut, VP professional pharmacy services at CVS/pharmacy. "To help ensure that patients take their medications appropriately and safely, it is important that they have all their prescriptions filled at the same pharmacy. CVS/pharmacy can fill all existing and new prescriptions for Tricare members."
Mylan launches generic version of Abbott’s Teveten
PITTSBURGH — Mylan has launched a generic drug for treating high blood pressure, the company said.
The drug maker announced the launch of eprosartan mesylate tablets in the 400-mg and 600-mg strengths. The drug is a generic version of Abbott’s Teveten and is used to treat hypertension.
Mylan was the first company to file a regulatory approval application with the Food and Drug Administration for the drug, thus entitling it to 180 days of market exclusivity in which to compete directly with Abbott. After that period, any company that wins approval from the FDA will be able to market a generic version of Teveten.
Teveten had sales of $4.9 million during the 12-month period ended in September, according to IMS Health.
FDA panel to review resubmitted NDA for pixantrone
SEATTLE — The Food and Drug Administration’s Oncologic Drugs Advisory Committee will review a resubmitted new drug application for a cancer treatment made by Cell Therapeutics.
The company said that the panel will review the NDA for pixantrone, which is designed to treat relapsed or refractory aggressive non-Hodgkin’s lymphoma in patients who failed two or more lines of prior therapy.
"We are pleased the FDA Office of Oncology Drug Products chose to bring our pixantrone NDA back to ODAC for review now that we have provided additional information and data recommended by the Office of New Drugs that we believe addresses the issues raised in the OODP complete response letter of April 2010," Cell Therapeutics CEO James Bianco said. "We believe the NDA demonstrates that pixantrone has a favorable benefit risk profile compared to standard chemotherapy in patients with relapsed or refractory aggressive NHL, a patient population for which there are no approved agents."
Cell Therapeutics noted that while the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the agency itself.